The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication
Open accessAbstract
In the EMPA-REG BP trial, empagliflozin 10 mg and 25 mg once daily reduced glycohemoglobin, blood pressure (BP), and weight versus placebo in patients with type 2 diabetes mellitus and hypertension. Patients received placebo (n=271), empagliflozin 10 mg (n=276), or empagliflozin 25 mg (n=276) for 12 weeks (n=full analysis set). This present analysis investigated changes from baseline to week 12 in mean 24-hour systolic BP (SBP) and diastolic BP (DBP) in patients receiving 0, 1, or ≥2 antihypertensive medications and patients receiving/not receiving diuretics or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Compared with placebo, empagliflozin 10 mg and 25 mg reduced mean 24-hour SBP/DBP in patients receiving 0 (10 mg: −3.89/−2.58 mm Hg; 25 mg: −3.77/−2.45 mm Hg), 1 (10 mg: −4.74/−1.97 mm Hg; 25 mg: −4.27/−1.81 mm Hg), or ≥2 (10 mg: −2.36/−0.68 mm Hg; 25 mg: −4.17/−1.54 mm Hg) antihypertensives. The effect of empagliflozin was not significantly different between subgroups by number of antihypertensives for changes in SBP (interaction P value 0.448) or DBP (interaction P value 0.498). Empagliflozin reduced 24-hour mean SBP/DBP irrespective of diuretic or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, with no significant difference between subgroups by use/no use of diuretics (interaction P values 0.380 [systolic]; 0.240 [diastolic]) or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (interaction P values 0.900 [systolic]; 0.359 [diastolic]). In conclusion, in patients with type 2 diabetes mellitus and hypertension, empagliflozin for 12 weeks reduced SBP and DBP versus placebo, irrespective of the number of antihypertensives and use of diuretics or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Clinical Trial Registration—: URL: https://clinicaltrials.gov . Unique identifier: NCT01370005.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The selection of medications to lower BP in persons with T2D should be guided by individual-specific considerations and may include nontraditional BP-lowering agents such as SGLT2is and GLP-1 RAs, though these drugs alone may be inadequate to control BP.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [241]
Experimental — accuracy not yet measuredIn the citing paper
“In the EMPA-REG BP trial, empagliflozin reduced mean 24 hour ambulatory systolic BP by approximately 3-4 mmHg after 12 weeks, 16 with consistent reductions irrespective of the number of background BP lowering drugs.17”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationStandards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,676
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010
Stark Casagrande, S., Fradkin, J. E., Saydah, S. H., Rust, K. F., & Cowie, C. C. (2013) · Diabetes Care · doi:10.2337/dc12-2258 · Cited by 719
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 584
Self-citationHandelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Self-citation
Cited by
Sorted by citations
Items 101–128 of 128
HIPERTENSÃO E DIABETES: CONCEITOS ATUAIS NA TERAPÊUTICA
Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Cosenso‐Martin, L. N., Yugar‐Toledo, J. C., Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Vilela-Martin, J. F., & Faculdade de Medicina de São José do Rio Preto (FAMERP), S. (2021) · Revista Brasileira de Hipertensão · doi:10.47870/1519-7522/20212803213-18 · Cited by 3
Hypertension and Type 2 Diabetes
Redón, J., & Martínez, F. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_3 · Cited by 2
Sanchez Ramiro, A. (2021) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2021.15.555908 · Cited by 1
New Antidiabetic Agents for the Treatment of Heart Failure in Hypertensive Patients
Nilsson, P. M., Holm, H., & Magnusson, M. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_23 · Cited by 1
Age-related disease: Cardiovascular system
Nilsson, P. M., Fossel, M., Bean, J., & Khera, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00010-4 · Cited by 2
Tao, X., Pan, T., Zhong, X., Du, Y., & Zhang, P. (2021) · PubMed Central · Cited by 1
SGLT-2 Inhibitors: Drug Selection by Means of the System of Objectified Judgement Analysis Method
Janknegt, R., Reinders, M., & Bianchi, R. (2021) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2021.05.0750
Saad, M., Gomceli, U., Ravi, P., Lacoste, A. G., Shah, N., & Vittorio, T. J. (2018) · Drugs in Context · doi:10.7573/dic.212549
Arterielle Hypertonie bei Menschen mit Diabetes
Zidek, W. (2019) · Der Diabetologe · doi:10.1007/s11428-018-0431-y
Arterielle Hypertonie bei Menschen mit Diabetes
Zidek, W. (2019) · Der Kardiologe · doi:10.1007/s12181-019-0342-1
Vowel Shift in Northern New Mexico Chicano English
Ho, J. (1993) · Mester
Changing the Landscape of Hypertension Management With SGLT2i
Bilić-Čurčić, I., Ninčević, V., Canecki-Varžić, S., Prpić-Kriẑevac, I., Ahić, J. M., & Mihaljević, I. (2022) · Southeastern European medical journal · doi:10.26332/seemedj.v6i1.247 · Cited by 1
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
SGLT 2 Inhibitors and Hypertension: Mild but Effective. What can we expect ?
Ivanović, B. (2022) · Journal of Cardiology & Cardiovascular Therapy · doi:10.19080/jocct.2022.18.555977
Évolution de la stratégie thérapeutique hors insuline dans le diabète de type 2
Vatier, C., & Bourcigaux, N. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.03.010
Nilsson, P. M. (2024) · doi:10.1002/9781119697473.ch47
SGLT2 Inhibitors and Mechanisms of Arterial Hypertension
Raimzhanov, A. A., & Mangasaryan, A. A. (2023) · Texas Journal of Medical Science · doi:10.62480/tjms.2023.vol18.pp13-16
“Unlike SGLT2, which is only expressed in the kidneys, SGLT1 is also expressed in the intestine, where it plays an important role in the absorption of glucose-galactose [10].”
Backgroundc. Part III: Treatment with Antidiabetes Drugs—Effects on Blood Pressure and Central Hemodynamics
Nilsson, P. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00011-8
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_8
Ураження нирок при артеріальній гіпертензії (діагностичні й терапевтичні аспекти)
Koval, S. M., Рєзнік, Л. А., Старченко, Т. Г., & Литвинова, О. М. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.369 · Cited by 1
Interaction of Renal Disease and Blood Pressure Control
Berbari, A. E., & Daouk, N. A. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_18
Clinical Interpretation of Modest Blood Pressure Changes After SGLT2 Inhibitor Initiation
Şahin, M. A., Karaarslan, O., Yılmaz, M. M., & Kalçık, M. (2026) · Journal of Clinical Hypertension · doi:10.1111/jch.70242
Dao, T., Lung, W.-C., Yang, Y.-Z., Chu, W., Tsan, Y., Chen, H.-Y., Chen, P., & Ho, W. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113282
Hsieh, W. C., Henry, B. M., & Édes, I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70907
Sodium–Glucose Cotransporter-2 Inhibitors for Renoprotection and Cardioprotection in CKD
Theodorakopoulou, M. P., & Iatridi, F. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_15
Adherence to Antihypertensive Medications in Chronic Kidney Disease
Damianaki, A., & Burnier, M. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_13
Mohammed, O., Kim, S. H., Karthikeyan, A., Eid, N., Reimann, R. S., Kanniyan, A. S., Joy, B., Dascălu, A.-C., Nanna, G. J., Acero, L. M. R., et al. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00817-1
Metadata
- Authors
- Mancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E.
- Affiliations
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Hypertension
- Published
- 2016-12
- Volume
- 68
- Issue
- 6
- Pages
- 1355-1364
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2530979034
- Cited by
- 128
- References
- 33
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 11 · 2021: 20 · 2020: 16 · 2019: 15 · 2018: 12 · 2017: 6 · 2016: 1
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (other-oa)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Alnylam Pharmaceuticals
- Regeneron Pharmaceuticals
- Kowa Company
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, type 2 diabetes, blood pressure reduction, antihypertensive drugs, diuretics, ACE inhibitors, angiotensin receptor blockers, 24-hour ambulatory blood pressure, SGLT2 inhibitors, subgroup analysis, dose comparison, weight loss, glycohemoglobin
- MeSH terms
- Antihypertensive Agents, Benzhydryl Compounds, Blood Glucose, Blood Pressure Determination, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Glucosides, Humans, Hypertension, Hypoglycemic Agents, Male, Prospective Studies, Reference Values, Severity of Illness Index, Comorbidity, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
